2451554
Project Grant
Overview
Grant Description
SBIR Phase I: Acoustic sensor based point of care diagnostic platform for rapid identification and antimicrobial susceptibility testing.
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project lies in addressing the growing global burden of antibiotic-resistant urinary tract infections (UTIs), which affect an estimated 150 million people annually.
Current diagnostic methods are slow, requiring days to deliver results, which delays effective treatment and contributes to antibiotic misuse.
This project seeks to develop a transformative diagnostic platform capable of identifying pathogens and determining their antimicrobial susceptibility within 60 minutes directly from unprocessed patient samples.
By enabling rapid, evidence-based treatment decisions at the point of care, this technology has the potential to improve patient outcomes, reduce healthcare costs, and combat the rise of antibiotic resistance.
Beyond healthcare, the platform’s adoption could enhance public health preparedness by providing scalable diagnostic solutions in various clinical settings.
This Small Business Innovation Research (SBIR) Phase I project focuses on advancing a next-generation diagnostic platform that integrates novel acoustic sensing technology.
The project will achieve three technical objectives:
(1) Demonstrate accurate antimicrobial susceptibility testing (AST) at pathogen loads as low as 10^3 colony-forming units per milliliter (CFU/mL),
(2) Validate AST against one antibiotic from six major classes, and
(3) Expand testing to include a diverse range of pathogens (gram-positive and gram-negative bacteria and fungal species).
Meeting these objectives will establish the technical feasibility of a point-of-care diagnostic capable of rapid and reliable pathogen identification and AST.
This innovation aims to address a critical unmet need in diagnostics, providing actionable results within 60 minutes at the point-of-care.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are not planned for this award.
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project lies in addressing the growing global burden of antibiotic-resistant urinary tract infections (UTIs), which affect an estimated 150 million people annually.
Current diagnostic methods are slow, requiring days to deliver results, which delays effective treatment and contributes to antibiotic misuse.
This project seeks to develop a transformative diagnostic platform capable of identifying pathogens and determining their antimicrobial susceptibility within 60 minutes directly from unprocessed patient samples.
By enabling rapid, evidence-based treatment decisions at the point of care, this technology has the potential to improve patient outcomes, reduce healthcare costs, and combat the rise of antibiotic resistance.
Beyond healthcare, the platform’s adoption could enhance public health preparedness by providing scalable diagnostic solutions in various clinical settings.
This Small Business Innovation Research (SBIR) Phase I project focuses on advancing a next-generation diagnostic platform that integrates novel acoustic sensing technology.
The project will achieve three technical objectives:
(1) Demonstrate accurate antimicrobial susceptibility testing (AST) at pathogen loads as low as 10^3 colony-forming units per milliliter (CFU/mL),
(2) Validate AST against one antibiotic from six major classes, and
(3) Expand testing to include a diverse range of pathogens (gram-positive and gram-negative bacteria and fungal species).
Meeting these objectives will establish the technical feasibility of a point-of-care diagnostic capable of rapid and reliable pathogen identification and AST.
This innovation aims to address a critical unmet need in diagnostics, providing actionable results within 60 minutes at the point-of-care.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are not planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH / SMALL BUSINESS TECHNOLOGY TRANSFER PHASE I PROGRAMS", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF24579
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Durham,
North Carolina
27701-5012
United States
Geographic Scope
Single Zip Code
Resonantia Diagnostics was awarded
Project Grant 2451554
worth $305,000
from National Science Foundation in March 2025 with work to be completed primarily in Durham North Carolina United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Project Grant was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase I Programs.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I: Acoustic Sensor Based Point of Care Diagnostic Platform for Rapid Identification and Antimicrobial Susceptibility Testing
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project lies in addressing the growing global burden of antibiotic-resistant urinary tract infections (UTIs), which affect an estimated 150 million people annually. Current diagnostic methods are slow, requiring days to deliver results, which delays effective treatment and contributes to antibiotic misuse. This project seeks to develop a transformative diagnostic platform capable of identifying pathogens and determining their antimicrobial susceptibility within 60 minutes directly from unprocessed patient samples. By enabling rapid, evidence-based treatment decisions at the point of care, this technology has the potential to improve patient outcomes, reduce healthcare costs, and combat the rise of antibiotic resistance. Beyond healthcare, the platform’s adoption could enhance public health preparedness by providing scalable diagnostic solutions in various clinical settings. This Small Business Innovation Research (SBIR) Phase I project focuses on advancing a next-generation diagnostic platform that integrates novel acoustic sensing technology. The project will achieve three technical objectives: (1) demonstrate accurate antimicrobial susceptibility testing (AST) at pathogen loads as low as 10^3 colony-forming units per milliliter (CFU/mL), (2) validate AST against one antibiotic from six major classes, and (3) expand testing to include a diverse range of pathogens (Gram-positive and Gram-negative bacteria and fungal species). Meeting these objectives will establish the technical feasibility of a point-of-care diagnostic capable of rapid and reliable pathogen identification and AST. This innovation aims to address a critical unmet need in diagnostics, providing actionable results within 60 minutes at the point-of-care. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and b
Topic Code
BM
Solicitation Number
NSF 24-579
Status
(Ongoing)
Last Modified 2/20/25
Period of Performance
3/1/25
Start Date
2/28/26
End Date
Funding Split
$305.0K
Federal Obligation
$0.0
Non-Federal Obligation
$305.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2451554
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
F3FJHCB8AA85
Awardee CAGE
8TJM2
Performance District
NC-04
Senators
Thom Tillis
Ted Budd
Ted Budd
Modified: 2/20/25